Exploiting the critical perioperative period to improve long-term cancer outcomes

Nature Reviews Clinical Oncology

Volumn 12, Issue 4, 2015, Pages 213-226

  Horowitz, Maya ^a   Neeman, Elad ^a   Sharon, Eran ^b   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOCAL ANESTHETIC AGENT; NARCOTIC ANALGESIC AGENT; OMEGA 3 FATTY ACID; PROPRANOLOL; PROSTAGLANDIN; SEX HORMONE;

ANALGESIA; ANESTHESIA INDUCTION; ANXIETY; BLOOD TRANSFUSION; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CATECHOLAMINE RELEASE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DRUG CHOICE; DRUG SAFETY; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; HORMONE BLOOD LEVEL; HUMAN; HYPOTHERMIA; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; LAPAROSCOPIC SURGERY; LONG TERM SURVIVAL; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MENTAL STRESS; METASTASIS; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; NEUROENDOCRINE SYSTEM; NONHUMAN; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PAIN; PARACRINE SIGNALING; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REGIONAL ANESTHESIA; REVIEW; STOMACH CANCER; STRESS; SURGICAL APPROACH; SURVIVAL TIME; TISSUE INJURY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

HUMANS; IMMUNE TOLERANCE; NEOPLASM METASTASIS; NEOPLASMS; NUTRITIONAL STATUS; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD; PROGNOSIS; RECURRENCE; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84925966184     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.224     Document Type: Review

References (220)

1. Neeman, E., Zmora, O. & Ben-Eliyahu, S. A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin. Cancer Res. 18, 4895-4902 (2012).
2. Neeman, E. & Ben-Eliyahu, S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav. Immun. 30 (Suppl.), S32-S40 (2013).
3. Snyder, G. L. & Greenberg, S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br. J. Anaesth. 105, 106-115 (2010).
4. Yamaguchi, K., Takagi, Y., Aoki, S., Futamura, M. & Saji, S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg. 232, 58-65 (2000).
5. Fisher, B., Gunduz, N., Coyle, J., Rudock, C. & Saffer, E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 49, 1996-2001 (1989).
6. OReilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
7. Abramovitch, R., Marikovsky, M., Meir, G. & Neeman, M. Stimulation of tumour growth by wound-derived growth factors. Br. J. Cancer 79, 1392-1398 (1999).
8. Armaiz-Pena, G. N., Cole, S. W., Lutgendorf, S. K. & Sood, A. K. Neuroendocrine influences on cancer progression. Brain Behav. Immun. 30 (Suppl.), S19-S25 (2013).
9. Gullino, P. M. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol. 34, 439-441 (1995).
10. Kim, R., Emi, M., Tanabe, K. & Arihiro, K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66, 5527-5536 (2006).
11. Badwe, R. et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J. Clin. Oncol. 29, 2845-2851 (2011).
12. Biki, B. et al. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 109, 180-187 (2008).
13. Exadaktylos, A. K., Buggy, D. J., Moriarty, D. C., Mascha, E. & Sessler, D. I. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 105, 660-664 (2006).
14. Desborough, J. P. The stress response to trauma and surgery. Br. J. Anaesth. 85, 109-117 (2000).
15. Shakhar, G. & Ben-Eliyahu, S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann. Surg. Oncol. 10, 972-992 (2003).
16. Buvanendran, A. et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology 104, 403-410 (2006).
17. Traynor, C. & Hall, G. M. Endocrine and metabolic changes during surgery: anaesthetic implications. Br. J. Anaesth. 53, 153-160 (1981).
18. Bartal, I. et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav. Immun. 24, 376-386 (2010).
19. Rosenne, E. et al. In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins. Brain Behav. Immun. 37, 207-219 (2014).
20. Perez-Sayans, M. et al. β-Adrenergic receptors in cancer: therapeutic implications. Oncol. Res. 19, 45-54 (2010).
21. Wu, W. K., Sung, J. J., Lee, C. W., Yu, J. & Cho, C. H. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 295, 7-16 (2010).
22. Mathew, B. et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth. Analg. 112, 558-567 (2011).
23. Bernabe, D. G., Tamae, A. C., Biasoli, E. R. & Oliveira, S. H. Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Brain Behav. Immun. 25, 574-583 (2011).
24. van der Bij, G. J. et al. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann. Surg. 249, 727-734 (2009).
25. Masur, K., Niggemann, B., Zanker, K. S. & Entschladen, F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by β-blockers. Cancer Res. 61, 2866-2869 (2001).
26. Kerros, C., Brood, I., Sola, B., Jauzac, P. & Allouche, S. Reduction of cell proliferation and potentiation of Fas-induced apoptosis by the selective kappa-opioid receptor agonist U50 488 in the multiple myeloma LP-1 cells. J. Neuroimmunol. 220, 69-78 (2010).
27. Roche-Nagle, G., Connolly, E. M., Eng, M., Bouchier-Hayes, D. J. & Harmey, J. H. Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br. J. Cancer 91, 359-365 (2004).
28. Sood, A. K. et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J. Clin. Invest. 120, 1515-1523 (2010).
29. Thaker, P. H. et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12, 939-944 (2006).
30. Wei, D. et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64, 2030-2038 (2004).
31. Yang, E. V. et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav. Immun. 23, 267-275 (2009).
32. Inbar, S. et al. Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity. PLoS ONE 6, e19246 (2011).
33. Kalinski, P. Regulation of immune responses by prostaglandin E2. J. Immunol. 188, 21-28 (2012).
34. Yakar, I. et al. Prostaglandin E2 suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann. Surg. Oncol. 10, 469-479 (2003).
35. Benish, M. et al. Perioperative use of β-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann. Surg. Oncol. 15, 2042-2052 (2008).
36. Glasner, A. et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a β-Adrenergic antagonist and a cyclooxygenase-2 inhibitor. J. Immunol. 184, 2449-2457 (2010).
37. Greenfeld, K. et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav. Immun. 21, 503-513 (2007).
38. Smyth, M. J. et al. Activation of NK cell cytotoxicity. Mol. Immunol. 42, 501-510 (2005).
39. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
40. Hodgson, D. M. & Knott, B. Potentiation of tumor metastasis in adulthood by neonatal endotoxin exposure: sex differences. Psychoneuroendocrinology 27, 791-804 (2002).
41. Dewan, M. Z. et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res. Treat. 104, 267-275 (2007).
42. Ben-Eliyahu, S., Page, G. G., Yirmiya, R. & Taylor, A. N. Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat. Med. 2, 457-460 (1996).
43. Goldfarb, Y. et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann. Surg. 253, 798-810 (2011).
44. Shakhar, G. & Ben-Eliyahu, S. In vivo β-Adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J. Immunol. 160, 3251-3258 (1998).
45. Landmann, R. β-Adrenergic receptors in human leukocyte subpopulations. Eur. J. Clin. Invest. 22 (Suppl. 1), 30-36 (1992).
46. Uotila, P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol. Immunother. 43, 1-9 (1996).
47. Ben-Eliyahu, S., Shakhar, G., Page, G. G., Stefanski, V. & Shakhar, K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and β-Adrenoceptors. Neuroimmunomodulation 8, 154-164 (2000).
48. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunitys roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
49. McCoy, J. L., Rucker, R. & Petros, J. A. Cell-mediated immunity to tumor-Associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res. Treat. 60, 227-234 (2000).
50. Detry, O., Honore, P., Meurisse, M. & Jacquet, N. Cancer in transplant recipients. Transplant. Proc. 32, 127 (2000).
51. Decaens, T. et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J. Gastroenterol. 12, 7319-7325 (2006).
52. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
53. Postow, M., Callahan, M. K. & Wolchok, J. D. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J. 17, 372-378 (2011).
54. Kim, J. W. & Eder, J. P. Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types. Oncology 28 (Suppl. 3), pii:202332 (2014).
55. Hegde, S., Fox, L., Wang, X. & Gumperz, J. E. Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. Immunology 130, 471-483 (2010).
56. Melamed, R. et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a β-Adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav. Immun. 19, 114-126 (2005).
57. Melamed, R. et al. The marginating-pulmonary immune compartment in rats: characteristics of continuous inflammation and activated NK cells. J. Immunother. 33, 16-29 (2010).
58. Luo, D. Z. et al. On the cell biology of pit cells, the liver-specific NK cells. World J. Gastroenterol. 6, 1-11 (2000).
59. Macleod, A. S. & Havran, W. L. Functions of skin-resident γσ T cells. Cell Mol. Life Sci. 68, 2399-2408 (2011).
60. Larmonier, N., Fraszczak, J., Lakomy, D., Bonnotte, B. & Katsanis, E. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol. Immunother. 59, 1-11 (2010).
61. Goldfarb, Y., Levi, B., Sorski, L., Frenkel, D. & Ben-Eliyahu, S. CpG-C immunotherapeutic efficacy is jeopardized by ongoing exposure to stress: potential implications for clinical use. Brain Behav. Immun. 25, 67-76 (2011).
62. Levi, B. et al. Continuous stress disrupts immunostimulatory effects of IL-12. Brain Behav. Immun. 25, 727-735 (2011).
63. Prigione, I. et al. Reciprocal interactions between human mesenchymal stem cells and γσ T cells or invariant natural killer T cells. Stem Cells 27, 693-702 (2009).
64. Martinet, L., Poupot, R. & Fournie, J. J. Pitfalls on the roadmap to γσ T cell-based cancer immunotherapies. Immunol. Lett. 124, 1-8 (2009).
65. Bodey, B., Bodey, B. Jr, Siegel, S. E. & Kaiser, H. E. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 20, 2665-2676 (1999).
66. Azrad, M. & Demark-Wahnefried, W. The association between adiposity and breast cancer recurrence and survival: a review of the recent literature. Curr. Nutr. Rep. 3, 9-15 (2014).
67. Chlebowski, R. T. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast 22 (Suppl. 2), S30-S37 (2013).
68. Heaney, A. & Buggy, D. J. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br. J. Anaesth. 109 (Suppl. 1), i17-i28 (2012).
69. Schlagenhauff, B. et al. Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res. 10, 165-169 (2000).
70. Myles, P. S. et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 342, d1491 (2011).
71. Gottschalk, A. et al. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 113, 27-34 (2010).
72. Tsui, B. C. et al. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can. J. Anaesth. 57, 107-112 (2010).
73. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00684229?term=NCT00684229 & rank=1 (2012).
74. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00418457?term=NCT00418457 & rank=1n (2013).
75. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01179308?term=NCT01179308 & rank=1 (2011).
76. Deegan, C. A. et al. Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro. Br. J. Anaesth. 103, 685-690 (2009).
77. Page, G. G., Ben Eliyahu, S., Yirmiya, R. & Liebeskind, J. C. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain 54, 21-28 (1993).
78. Shavit, Y., Ben-Eliyahu, S., Zeidel, A. & Beilin, B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 11, 255-260 (2004).
79. Afsharimani, B., Doornebal, C. W., Cabot, P. J., Hollmann, M. W. & Parat, M. O. Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br. J. Pharmacol. http://dx.doi.org/10.1111/bph.12589 (2014).
80. Bayer, B. M., Daussin, S., Hernandez, M. & Irvin, L. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 29, 369-374 (1990).
81. Yeager, M. P. et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 83, 500-508 (1995).
82. Page, G. G., Ben-Eliyahu, S., Yirmiya, R. & Liebeskind, J. C. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain 54, 21-28 (1993).
83. Gaspani, L., Bianchi, M., Limiroli, E., Panerai, A. E. & Sacerdote, P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J. Neuroimmunol. 129, 18-24 (2002).
84. Melamed, R., Bar-Yosef, S., Shakhar, G., Shakhar, K. & Ben-Eliyahu, S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth. Analg. 97, 1331-1339 (2003).
85. Ben-Eliyahu, S., Shakhar, G., Rosenne, E., Levinson, Y. & Beilin, B. Hypothermia in barbiturate-Anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology 91, 732-740 (1999).
86. Gupta, A., Bjornsson, A., Fredriksson, M., Hallbook, O. & Eintrei, C. Reduction in mortality after epidural anaesthesia and analgesia in patients undergoing rectal but not colonic cancer surgery: a retrospective analysis of data from 655 patients in central Sweden. Br. J. Anaesth. 107, 164-170 (2011).
87. Lin, L. et al. Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br. J. Anaesth. 106, 814-822 (2011).
88. Cata, J. P., Gottumukkala, V. & Sessler, D. I. How regional analgesia might reduce postoperative cancer recurrence. Eur. J. Pain Suppl. 5, 345-355 (2011).
89. Kao, K. J. Mechanisms and new approaches for the allogeneic blood transfusion-induced immunomodulatory effects. Transfus. Med. Rev. 14, 12-22 (2000).
90. Lenhard, V., Maassen, G. & Opelz, G. Transfusion-induced enhancement of prostaglandin and thromboxane release in prospective kidney graft recipients. Proc. Eur. Dial. Transplant. Assoc. Eur. Ren. Assoc. 21, 923-927 (1985).
91. Jensen, L. S. et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br. J. Surg. 79, 513-516 (1992).
92. Blumberg, N. & Heal, J. M. Effects of transfusion on immune function. Cancer recurrence and infection. Arch. Pathol. Lab. Med. 118, 371-379 (1994).
93. Schriemer, P. A., Longnecker, D. E. & Mintz, P. D. The possible immunosuppressive effects of perioperative blood transfusion in cancer patients. Anesthesiology 68, 422-428 (1988).
94. Landers, D. F., Hill, G. E., Wong, K. C. & Fox, I. J. Blood transfusion-induced immunomodulation. Anesth. Analg. 82, 187-204 (1996).
95. Acheson, A. G., Brookes, M. J. & Spahn, D. R. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-Analysis. Ann. Surg. 256, 235-244 (2012).
96. Amato, A. & Pescatori, M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD005033. http://dx.doi.org/10.1002/14651858.CD005033.pub2.
97. Rosenberg, S. A., Seipp, C. A., White, D. E. & Wesley, R. Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-Tissue sarcomas of the extremities. J. Clin. Oncol. 3, 698-709 (1985).
98. Johnson, J. T., Taylor, F. H. & Thearle, P. B. Blood transfusion and outcome in stage III head and neck carcinoma. Arch. Otolaryngol. Head Neck Surg. 113, 307-310 (1987).
99. Atzil, S. et al. Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology 109, 989-997 (2008).
100. Gohel, M. S., Bulbulia, R. A., Slim, F. J., Poskitt, K. R. & Whyman, M. R. How to approach major surgery where patients refuse blood transfusion (including Jehovahs Witnesses). Ann. R. Coll. Surg. Engl. 87, 3-14 (2005).
101. Martyn, V. et al. The theory and practice of bloodless surgery. Transfus. Apher. Sci. 27, 29-43 (2002).
102. Kurz, A., Sessler, D. I. & Lenhardt, R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. N. Engl. J. Med. 334, 1209-1215 (1996).
103. Beilin, B. et al. Effects of mild perioperative hypothermia on cellular immune responses. Anesthesiology 89, 1133-1140 (1998).
104. Frank, S. M. et al. The catecholamine, cortisol, and hemodynamic responses to mild perioperative hypothermia. A randomized clinical trial. Anesthesiology 82, 83-93 (1995).
105. Rajagopalan, S., Mascha, E., Na, J. & Sessler, D. I. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. Anesthesiology 108, 71-77 (2008).
106. Kurz, A., Sessler, D. I. & Lenhardt, R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N. Engl. J. Med. 334, 1209-1215 (1996).
107. Nduka, C. C. et al. Intraperitoneal hypothermia during surgery enhances postoperative tumor growth. Surg. Endosc. 16, 611-615 (2002).
108. Walker, J. L. et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J. Clin. Oncol. 27, 5331-5336 (2009).
109. van der Pas, M. H. et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-Term outcomes of a randomised, phase 3 trial. Lancet Oncol. 14, 210-218 (2013).
110. Breukink, S., Pierie, J. & Wiggers, T. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD005200. http://dx.doi.org/10.1002/14651858.CD005200.pub3.
111. Schwenk, W., Haase, O., Neudecker, J. & Muller, J. M. Short term benefits for laparoscopic colorectal resection. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003145. http://dx.doi.org/10.1002/14651858.CD003145.pub2.
112. Wu, F. P. et al. Systemic and peritoneal inflammatory response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. Dis. Colon Rectum 46, 147-155 (2003).
113. Sammour, T., Kahokehr, A., Chan, S., Booth, R. J. & Hill, A. G. The humoral response after laparoscopic versus open colorectal surgery: a meta-Analysis. J. Surg. Res. 164, 28-37 (2010).
114. Torres, A., Torres, K., Paszkowski, T., Staskiewicz, G. J. & Maciejewski, R. Cytokine response in the postoperative period after surgical treatment of benign adnexal masses: comparison between laparoscopy and laparotomy. Surg. Endosc. 21, 1841-1848 (2007).
115. Sammour, T., Kahokehr, A., Zargar-Shoshtari, K. & Hill, A. G. A prospective case-control study of the local and systemic cytokine response after laparoscopic versus open colonic surgery. J. Surg. Res. 173, 278-285 (2012).
116. Wichmann, M. W. et al. Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch. Surg. 140, 692-697 (2005).
117. Landman, J. et al. Prospective comparison of the immunological and stress response following laparoscopic and open surgery for localized renal cell carcinoma. J. Urol. 171, 1456-1460 (2004).
118. Hu, J. K. et al. Comparative evaluation of immune response after laparoscopical and open total mesorectal excisions with anal sphincter preservation in patients with rectal cancer. World J. Gastroenterol. 9, 2690-2694 (2003).
119. Solomon, M. J., Young, C. J., Eyers, A. A. & Roberts, R. A. Randomized clinical trial of laparoscopic versus open abdominal rectopexy for rectal prolapse. Br. J. Surg. 89, 35-39 (2002).
120. Lacy, A. M. et al. Laparoscopy-Assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 359, 2224-2229 (2002).
121. Kuhry, E., Schwenk, W. F., Gaupset, R., Romild, U. & Bonjer, H. J. Long-Term results of laparoscopic colorectal cancer resection. Cochrane Database of Systematic Review, Issue 2. Art. No.: CD003432. http://dx.doi.org/10.1002/14651858.CD003432.pub2.
122. Galaal, K. et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database of Systematic Review, Issue 9. Art. No.: CD006655. http://dx.doi.org/10.1002/14651858.CD006655.pub2.
123. Lawrie, T. A. et al. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database of Systematic Review, Issue 2. Art. No.: CD005344. http://dx.doi.org/10.1002/14651858.CD005344.pub3.
124. Sorski, L. et al. The impact of surgical extent and sex on the hepatic metastasis of colon cancer. Surg. Today 44, 1925-1934 (2014).
125. Sorski, L. et al. Do minimally-invasive surgical procedures reduce colorectal cancer progression? A severity-independent need for arresting surgically-induced stress responses using β-Adrenergic blockers and COX2 inhibitors. Brain Behav. Immun. 25, S200 (2011).
126. Hrushesky, W. J., Bluming, A. Z., Gruber, S. A. & Sothern, R. B. Menstrual influence on surgical cure of breast cancer. Lancet 2, 949-952 (1989).
127. Badwe, R. A. et al. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 337, 1261-1264 (1991).
128. Lemon, H. M. & Rodriguez-Sierra, J. F. Timing of breast cancer surgery during the luteal menstrual phase may improve prognosis. Nebr. Med. J. 81, 73-78 (1996).
129. Samuel, M., Wai, K. L., Brennan, V. K. & Yong, W. S. Timing of breast surgery in premenopausal breast cancer patients. Cochrane Database of Systematic Review, Issue 5. Art. No.: CD003720. http://dx.doi.org/10.1002/14651858.CD003720.pub2.
130. Ben-Eliyahu, S., Page, G. G., Shakhar, G. & Taylor, A. N. Increased susceptibility to metastasis during pro-oestrus/oestrus in rats: possible role of oestradiol and natural killer cells. Br. J. Cancer 74, 1900-1907 (1996).
131. Ben-Eliyahu, S., Shakhar, G., Shakhar, K. & Melamed, R. Timing within the oestrous cycle modulates adrenergic suppression of NK activity and resistance to metastasis: possible clinical implications. Br. J. Cancer 83, 1747-1754 (2000).
132. Shakhar, K., Shakhar, G., Rosenne, E. & Ben-Eliyahu, S. Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of NK cell activity. Br. J. Cancer 83, 1630-1636 (2000).
133. Page, G. G. & Ben-Eliyahu, S. Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus/estrus in rats. Breast Cancer Res. Treat. 45, 159-167 (1997).
134. Wheeldon, N. M. et al. Influence of sex-steroid hormones on the regulation of lymphocyte β2-Adrenoceptors during the menstrual cycle. Br. J. Clin. Pharmacol. 37, 583-588 (1994).
135. Grant, C. S. et al. Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J. Clin. Oncol. 27, 3620-3626 (2009).
136. Lutgendorf, S., Costanzo, E. & Siegel, S. Psychosocial influences in oncology: an expanded model of biobehavioral mechanisms. Psychoneuroimmunology 4, 869-896 (2007).
137. Garssen, B., Boomsma, M. F. & Beelen, R. H. Psychological factors in immunomodulation induced by cancer surgery: a review. Biol. Psychol. 85, 1-13 (2010).
138. Stefanski, V. & Ben-Eliyahu, S. Social confrontation and tumor metastasis in rats: defeat and β-Adrenergic mechanisms. Physiol. Behav. 60, 277-282 (1996).
139. Fawzy, F. I. et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch. Gen. Psychiatry 50, 681-689 (1993).
140. Kuchler, T., Bestmann, B., Rappat, S., Henne-Bruns, D. & Wood-Dauphinee, S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J. Clin. Oncol. 25, 2702-2708 (2007).
141. Andersen, B. L. et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 113, 3450-3458 (2008).
142. Andersen, B. L. et al. Stress and immune responses after surgical treatment for regional breast cancer. J. Natl Cancer Inst. 90, 30-36 (1998).
143. Koga, C. et al. Anxiety and pain suppress the natural killer cell activity in oral surgery outpatients. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 91, 654-658 (2001).
144. Levy, S. M. et al. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom. Med. 52, 73-85 (1990).
145. Phillips, K. M. et al. Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom. Med. 70, 1044-1049 (2008).
146. Antoni, M. H. et al. Cognitive-behavioral stress management reverses anxiety-related leukocyte transcriptional dynamics. Biol. Psychiatry 71, 366-372 (2012).
147. Ross, L., Boesen, E. H., Dalton, S. O. & Johansen, C. Mind and cancer: does psychosocial intervention improve survival and psychological well-being? Eur. J. Cancer 38, 1447-1457 (2002).
148. Edelman, S., Lemon, J., Bell, D. R. & Kidman, A. D. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology 8, 474-481 (1999).
149. Ross, L. et al. No effect on survival of home psychosocial intervention in a randomized study of Danish colorectal cancer patients. Psychooncology 18, 875-885 (2009).
150. Huhmann, M. B. & August, D. A. Perioperative nutrition support in cancer patients. Nutr. Clin. Pract. 27, 586-592 (2012).
151. Gupta, D. & Lis, C. G. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr. J. 9, 69 (2010).
152. Buijs, N. et al. Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-Term survival. Am. J. Clin. Nutr. 92, 1151-1156 (2010).
153. Winkels, R. M. et al. The COLON study: Colorectal cancer: Longitudinal, Observational study on Nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer 14, 374 (2014).
154. Lee, J. W. et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin. Cancer Res. 15, 2695-2702 (2009).
155. Rothwell, P. M. et al. Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602-1612 (2012).
156. Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K. & Visvanathan, K. Beta blockers and breast cancer mortality: a population-based study. J. Clin. Oncol. 29, 2635-2644 (2011).
157. Powe, D. G. et al. β-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1, 628-638 (2010).
158. Watkins, J. et al. Improved outcomes with beta blocker use in epithelial ovarian cancer patients [abstract]. Gynecol. Oncol. 130, e31 (2013).
159. Liu, J. F., Jamieson, G. G., Wu, T. C., Zhu, G. J. & Drew, P. A. A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann. Surg. Oncol. 16, 1397-1402 (2009).
160. Martin, L. A. et al. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res. Treat. 123, 829-836 (2010).
161. Dhawan, D. et al. Effects of short-Term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol. Cancer. Ther. 9, 1371-1377 (2010).
162. Sooriakumaran, P. et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res. 29, 1483-1488 (2009).
163. Forget, P. et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann. Surg. Oncol. 20 (Suppl. 3), 650-660 (2013).
164. Melhem-Bertrandt, A. et al. β-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J. Clin. Oncol. 29, 2645-2652 (2011).
165. Lemeshow, S. et al. β-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol. Biomarkers Prev. 20, 2273-2279 (2011).
166. Hazut, O. et al. The effect of β-Adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis. Int. J. Clin. Pharmacol. Ther. 49, 545-554 (2011).
167. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00888797?term=NCT00888797 & rank=1 (2011).
168. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00502684?term=NCT00502684 & rank=1 (2014).
169. Rader, D. J. & Hobbs, H. H. in Harrisons Principles of Internal Medicine 16th edn Ch. 335 (ed. Kasper D. L.) 2286-2319 (McGraw-Hill, 2005).
170. Narisawa, T. et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J. Cancer Res. 87, 798-804 (1996).
171. Berquin, I. M., Edwards, I. J. & Chen, Y. Q. Multi-Targeted therapy of cancer by omega-3 fatty acids. Cancer Lett. 269, 363-377 (2008).
172. Liakopoulos, O. J. et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-Analysis of over 30,000 patients. Eur. Heart J. 29, 1548-1559 (2008).
173. Graaf, M. R., Richel, D. J., van Noorden, C. J. & Guchelaar, H. J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 30, 609-641 (2004).
174. Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792-1802 (2012).
175. Poynter, J. N. et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352, 2184-2192 (2005).
176. Hamilton, R. J. et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116, 3389-3398 (2010).
177. Dellavalle, R. P. et al. Statins and fibrates for preventing melanoma. Cochrane Database of Systematic Review, Issue 4. Art. No.: CD003697. http://dx.doi.org/10.1002/14651858.CD003697.pub2.
178. Kawata, S. et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84, 886-891 (2001).
179. Matar, P. et al. Inhibitory effect of lovastatin on spontaneous metastases derived from a rat lymphoma. Clin. Exp. Metastasis 17, 19-25 (1999).
180. Garwood, E. R. et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 119, 137-144 (2010).
181. Pollack, A. et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J. Clin. Oncol. 22, 2133-2140 (2004).
182. Zhao, J. et al. TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and p53 expression. Human Pathology 38, 293-298 (2007).
183. Weiss, G. et al. Immunomodulation by perioperative administration of n-3 fatty acids. Br. J. Nutr. 87 (Suppl. 1), S89-S94 (2002).
184. Ates, E. et al. Perioperative immunonutrition ameliorates the postoperative immune depression in patients with gastrointestinal system cancer (prospective clinical study in 42 patients). Acta Gastroenterol. Belg. 67, 250-254 (2004).
185. Berger, M. M. et al. Three short perioperative infusions of n-3 PUFAs reduce systemic inflammation induced by cardiopulmonary bypass surgery: a randomized controlled trial. Am. J. Clin. Nutr. 97, 246-254 (2013).
186. Goldfarb, Y. et al. Fish oil attenuates surgery-induced immunosuppression, limits post-operative metastatic dissemination and increases long-Term recurrence-free survival in rodents inoculated with cancer cells. Clin. Nutr. 31, 396-404 (2012).
187. Murphy, R. A. et al. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117, 3774-3780 (2011).
188. Hubbard, N. E., Lim, D. & Erickson, K. L. Alteration of murine mammary tumorigenesis by dietary enrichment with n-3 fatty acids in fish oil. Cancer Lett. 124, 1-7 (1998).
189. Calder, P. C. n-3 fatty acids, inflammation, and immunity-relevance to postsurgical and critically ill patients. Lipids 39, 1147-1161 (2004).
190. Tziakas, D. N. et al. Effect of statins on collagen type I degradation in patients with coronary artery disease and atrial fibrillation. Am. J. Cardiol. 101, 199-202 (2008).
191. Dernellis, J. & Panaretou, M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am. Heart J. 150, 1064 (2005).
192. Hakamada-Taguchi, R. et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces TH1 development and promotes TH2 development. Circ. Res. 93, 948-956 (2003).
193. Ikeda, U. & Shimada, K. Statins and monocytes. Lancet 353, 2070 (1999).
194. Thibault, A. et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2, 483-491 (1996).
195. Jakobisiak, M., Bruno, S., Skierski, J. S. & Darzynkiewicz, Z. Cell cycle-specific effects of lovastatin. Proc. Natl Acad. Sci. USA 88, 3628-3632 (1991).
196. Dimitroulakos, J. et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93, 1308-1318 (1999).
197. Dimitroulakos, J. & Yeger, H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat. Med. 2, 326-333 (1996).
198. Dimitroulakos, J. et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin. Cancer Res. 7, 158-167 (2001).
199. Xiao, H. & Yang, C. S. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int. J. Cancer 123, 983-990 (2008).
200. Xiao, H., Zhang, Q., Lin, Y., Reddy, B. S. & Yang, C. S. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int. J. Cancer 122, 2115-2124 (2008).
201. Zheng, X. et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin. Cancer Res. 13, 5480-5487 (2007).
202. Reddy, B. S. et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res. 66, 4542-4546 (2006).
203. Avraham, R. et al. Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. Brain Behav. Immun. 24, 952-958 (2010).
204. Bohm, M. et al. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma. Folia Biol. (Praha) 49, 63-68 (2003).
205. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484 (2006).
206. Novakovic, S., Stegel, V., Kopitar, A., Ihan, A. & Novakovic, B. J. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine 25, 8241-8256 (2007).
207. Kunikata, N. et al. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells. J. Invest. Dermatol. 123, 395-402 (2004).
208. Kuramoto, Y., Nishikawa, M., Hyoudou, K., Yamashita, F. & Hashida, M. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J. Control Release 115, 226-233 (2006).
209. Goldfarb, Y. et al. CpG-C oligodeoxynucleotides limit the deleterious effects of β-Adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination. J. Immunother. 32, 280-291 (2009).
210. Lubaroff, D. M. et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin. Cancer Res. 15, 7375-7380 (2009).
211. Smith, D. A. et al. Efficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy [abstract]. J. Clin. Oncol. 30 (Suppl.), e18047 (2012).
212. Behzad, H. et al. GLA-SE, a synthetic Toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205, 466-473 (2012).
213. Matzner, P. et al. 87. The use of the newly developed synthetic TLR-4 agonistas an immuno-Therapeutic agent in a cancer model. Brain Behav. Immun. 32 (Suppl.), e25 (2013).
214. Schwartz, Y., Avraham, R., Benish, M., Rosenne, E. & Ben-Eliyahu, S. Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Res. Treat. 107, 211-223 (2008).
215. Faries, M. B., Hsueh, E. C., Ye, X., Hoban, M. & Morton, D. L. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin. Cancer Res. 15, 7029-7035 (2009).
216. Varadhan, K. K., Lobo, D. N. & Ljungqvist, O. Enhanced recovery after surgery: the future of improving surgical care. Crit. Care Clin. 26, 527-547 (2010).
217. Gatt, M., Khan, S. & MacFie, J. In response to: Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-Analysis of randomized controlled trials. Clin. Nutr. 29 434-440 (2010).
218. Lv, L., Shao, Y. F. & Zhou, Y. B. The enhanced recovery after surgery (ERAS) pathway for patients undergoing colorectal surgery: an update of meta-Analysis of randomized controlled trials. Int. J. Colorectal Dis. 27, 1549-1554 (2012).
219. Ren, L. et al. Enhanced Recovery After Surgery (ERAS) program attenuates stress and accelerates recovery in patients after radical resection for colorectal cancer: a prospective randomized controlled trial. World J. Surg. 36, 407-414 (2012).
220. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).